<DOC>
	<DOC>NCT00417391</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of 1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's disease.</brief_summary>
	<brief_title>Phase II Study of RR110 in Patients With Active Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Patients with CDAI score ranging from 220 to 450 Patients with CRP &gt; 1 mg/dL Patients who can be hospitalized at least 2 weeks after first administration Patients who have previously used antiTNF antibody, cyclosporine, methotrexate or tacrolimus within 12 weeks of screening Patients who have had surgical bowel resections within 4 weeks of screening Patients who have previously used total parental nutrition or more than 900 kcal/day of enteral nutrition within 4 weeks of screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>